FXR agonist 17 is an orally active, steroidal FXR agonist with EC 50 values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), respectively. FXR agonist 17 activates TGR5 ( EC 50 = 2.6 μM) but does not activate hMRGPRX4. FXR agonist 17 exerts anti-inflammatory, hepatoprotective and antifibrotic effects, improves the non-alcoholic steatohepatitis (NAFLD) activity score and reduces the severity of liver fibrosis. FXR agonist 17 can be used for the research of NAFLD, cholestatic liver disease and liver fibrosis.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > FXR | Products > Signaling Pathways > G protein-coupled Bile Acid Receptor 1 | Products > Signaling Pathways > TNF Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.